CoChat
Sign Up
Cited by 205Antifungal resistance and susceptibilityYeasts and Rust Fungi StudiesFungal Plant Pathogen Control

Candida auris and multidrug resistance: Defining the new normal

Open access
Lockhart, Shawn R.·2019·Fungal Genetics and Biology
DOI 10.1016/j.fgb.2019.103243PMC PMC12012538
Open this paper in CoChat — free account

Abstract

Candida auris is an emerging species of yeast characterized by colonization of skin, persistence in the healthcare environment, and antifungal resistance. C. auris was first described in 2009 from a single isolate but has since been reported in more than 25 countries worldwide. Resistance to fluconazole and amphotericin B is common, and resistance to the echinocandins is emerging in some countries. Antifungal resistance has been shown to be acquired rather than intrinsic and the primary mechanisms of resistance to the echinocandins and azoles have been determined. There are a number of new antifungal agents in phase 2 and phase 3 clinical trials and many have activity against C. auris. This review will discuss what is currently known about antifungal resistance in C. auris, limitations to antifungal susceptibility testing, the mechanisms of resistance, and the new antifungals that are on the horizon.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.fgb.2019.103243

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 68

  1. Abastabar M,, 2019. Candida auris otomycosis in Iran and review of recent literature. Mycoses 62, 101– 105. 30585653
  2. Ahmad A,, 2019. A high-throughput and rapid method for accurate identification of emerging multidrug-resistant Candida auris. Mycoses 62, 513– 518. 30801778 PMC10888143
  3. Arauz AB,, 2018. Isolation of Candida auris from 9 patients in Central America: importance of accurate diagnosis and susceptibility testing. Mycoses 61, 44– 47. 28945325
  4. Arendrup MC,, 2018. APX001A in vitro activity against contemporary blood isolates and Candida auris determined by the EUCAST reference method. Antimicrob. Agents Chemother. 62, e01225– e1318. 30104264 PMC6153824
  5. Arendrup MC,, 2017. Comparison of EUCAST and CLSI reference microdilution MICs of eight antifungal compounds for Candida auris and associated tentative epidemiological cutoff values. Antimicrob. Agents Chemother. 61, e00485– e517. 28416539 PMC5444165
  6. Ben-Ami R,, 2017. Multidrug-resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg. Infect. Dis. 23. 10.3201/eid2302. PMC5324804 28098529 · DOI
  7. Berkow EL,, 2017. In vitro activity of a novel glucan synthase inhibitor, SCY-078, against clinical Isolates of Candida auris. Antimicrob. Agents Chemother. 61, e00435– e517. 28483955 PMC5487607
  8. Berkow EL, Lockhart SR, 2017. Fluconazole resistance in Candida species: a current perspective. Infect. Drug Resist. 10, 237– 245. 28814889 PMC5546770
  9. Berkow EL, Lockhart SR, 2018b. Activity of novel antifungal compound APX001A against a large collection of Candida auris. J. Antimicrob. Chemother. 73, 3060– 3062. 30085167
  10. Bhattacharya S,, 2019. Gene duplication associated with increased fluconazole tolerance in Candida auris cells of advanced generational age. Sci. Rep. 9, 5052. 30911079 PMC6434143
  11. Calvo B,, 2016. First report of Candida auris in America: clinical and microbiological aspects of 18 episodes of candidemia. J. Infect. 73, 369– 374. 27452195
  12. Cendejas-Bueno E,, 2012. Reclassification of the Candida haemulonii complex as Candida haemulonii (C. haemulonii group I), C. duobushaemulonii sp. nov. (C. haemulonii group II), and C. haemulonii var. vulnera var. nov.: three multiresistant human pathogenic yeasts. J. Clin. Microbiol. 50, 3641– 3651. 22952266 PMC3486233
  13. Chamilos G,, 2007. Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob. Agents Chemother. 51, 2257– 2259. 17438060 PMC1891358
  14. Chowdhary A,, 2018. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009–17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J. Antimicrob. Chemother. 73, 891– 899. 29325167
  15. Chowdhary A,, 2013. New clonal strain of Candida auris, Delhi, India. Emerg. Infect. Dis. 19, 1670– 1673. 24048006 PMC3810747
  16. Chowdhary A,, 2016. Multidrug-resistant Candida auris: ‘new kid on the block’ in hospital-associated infections? J. Hosp. Infect. 94, 209– 212. 27634564
  17. Ellis D, 2002. Amphotericin B: spectrum and resistance. J. Antimicrob. Chemother. 49 (Suppl 1), 7– 10. 11801575
  18. Espinel-Ingroff A,, 2013. Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob. Agents Chemother. 57, 5836– 5842. 24018263 PMC3837874
  19. Flowers SA,, 2015. Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans. Antimicrob. Agents Chemother. 59, 450– 460. 25385095 PMC4291385
  20. Hager CL,, 2018a. In vitro and in vivo evaluation of the antifungal activity of APX001A/APX001 against Candida auris. Antimicrob. Agents Chemother. 62, e02319– e2417. 29311065 PMC5826120
  21. Hager CL,, 2018b. Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model. J. Antimicrob. Chemother. 73, 2085– 2088. 29897469 PMC6070025
  22. Hebert MF,, 2005. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J. Clin. Pharmacol. 45, 1145– 1152. 16172179
  23. Jeffery-Smith A,, 2018. Candida auris: a review of the literature. Clin. Microbiol. Rev. 31, e00029– e117. 29142078 PMC5740969
  24. Kathuria S,, 2015. Multidrug-resistant Candida auris misidentified as Candida haemulonii: characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI Broth Microdilution, and Etest Method. J. Clin. Microbiol. 53, 1823– 1830. 25809970 PMC4432077
  25. Kim MN,, 2009. Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin. Infect. Dis. 48, e57– e61. 19193113
  26. Kordalewska M,, 2018. Understanding echinocandin resistance in the emerging pathogen Candida auris. Antimicrob. Agents Chemother. 62, e00238– e318. 29632013 PMC5971591
  27. Kumar D,, 2015. Itraconazole-resistant Candida auris with phospholipase, proteinase and hemolysin activity from a case of vulvovaginitis. J. Infect. Dev. Ctries. 9, 435– 437. 25881537
  28. Kwon YJ,, 2019. Candida auris clinical Isolates from South Korea: identification, antifungal susceptibility, and genotyping. J. Clin. Microbiol. 57, e01624– e1718. 30728190 PMC6440790
  29. Lamoth F,, 2018. Changes in the epidemiological landscape of invasive candidiasis. J. Antimicrob. Chemother. 73, i4– i13. 29304207 PMC11931512
  30. Leach L,, 2018. Development and validation of a real-time PCR Assay for rapid detection of Candida auris from surveillance samples. J. Clin. Microbiol. 56, e01223– e1317. 29187562 PMC5786737
  31. Lee WG,, 2011. First three reported cases of nosocomial fungemia caused by Candida auris. J. Clin. Microbiol. 49, 3139– 3142. 21715586 PMC3165631
  32. Lepak AJ,, 2017. Pharmacodynamic optimization for treatment of invasive Candida auris infection. Antimicrob. Agents Chemother. 61, e00791– e817. 28584152 PMC5527602
  33. Lockhart SR,, 2017a. Candida auris for the clinical microbiology laboratory: not your grandfather’s Candida species. Clin. Microbiol. Newsl. 39, 99– 103. 29503491 PMC5831145
  34. Lockhart SR,, 2017b. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin. Infect. Dis. 64, 134– 140. 27988485 PMC5215215
  35. Lockhart SR,, 2012. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J. Clin. Microbiol. 50, 3435– 3442. 22875889 PMC3486211
  36. Lone SA, Ahmad A, 2019. Candida auris - the growing menace to global health. Mycoses. 30773703
  37. Magobo RE,, 2014. Candida auris-associated candidemia, South Africa. Emerg Infect Dis. 20, 1250– 1251. 24963796 PMC4073876
  38. Martinez-Murcia A,, 2018. Internal validation of GPS() MONODOSE CanAur dtecqPCR kit following the UNE/EN ISO/IEC 17025:2005 for detection of the emerging yeast Candida auris. Mycoses 61, 877– 884. 30059175
  39. Mathur P,, 2018. Five-year profile of Candida emia at an Indian trauma centre: high rates of Candida auris blood stream infections. Mycoses 61, 674– 680. 29738604
  40. Morales-Lopez SE,, 2017. Invasive Infections with Multidrug-Resistant Yeast Candida auris, Colombia. Emerg. Infect. Dis. 23, 162– 164. 27983941 PMC5176232
  41. Munoz JF,, 2018. Genomic insights into multidrug-resistance, mating and virulence in Candida auris and related emerging species. Nat. Commun. 9, 5346. 30559369 PMC6297351
  42. Perea S,, 2001. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 45, 2676– 2684. 11557454 PMC90716
  43. Perlin DS, 2015. Mechanisms of echinocandin antifungal drug resistance. Ann. N. Y. Acad. Sci. 1354, 1– 11. 26190298 PMC4626328
  44. Perlin DS,, 2017. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect. Dis. 17, e383– e392. 28774698
  45. Prakash A,, 2016. Evidence of genotypic diversity among Candida auris isolates by multilocus sequence typing, matrix-assisted laser desorption ionization time-of-flight mass spectrometry and amplified fragment length polymorphism. Clin. Microbiol. Infect. 22, 277 e1– 9. 26548511
  46. Revie NM,, 2018. Antifungal drug resistance: evolution, mechanisms and impact. Curr. Opin. Microbiol. 45, 70– 76. 29547801 PMC6135714
  47. Rhodes J,, 2018. Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris. Emerg. Microbes. Infect. 7, 43. 29593275 PMC5874254
  48. Robbins N,, 2017. Molecular evolution of antifungal drug resistance. Annu. Rev. Microbiol. 71, 753– 775. 28886681
  49. Rudramurthy SM,, 2017. Candida auris Candida emia in Indian ICUs: analysis of risk factors. J. Antimicrob. Chemother. 72, 1794– 1801. 28333181
  50. Ruiz-Gaitan A,, 2018. An outbreak due to Candida auris with prolonged colonisation and Candida emia in a tertiary care European hospital. Mycoses 61, 498– 505. 29655180
  51. Ruiz-Gaitan AC,, 2019. Outbreak of Candida auris in Spain: a comparison of antifungal activity by three methods with published data. Int. J. Antimicrob. Agents 53, 541– 546. 30769198
  52. Ruiz Gaitan AC,, 2017. Nosocomial fungemia by Candida auris: first four reported cases in continental Europe. Rev. Iberoam. Micol. 34, 23– 27. 28131716
  53. Rybak JM,, 2019. Abrogation of triazole resistance upon deletion of CDR1 in a clinical Isolate of Candida auris. Antimicrob. Agents Chemother. 63, e00057– e119. 30718246 PMC6437491
  54. Ryder NS,, 1998. In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts. Antimicrob. Agents Chemother. 42, 1057– 1061. 9593126 PMC105744
  55. Satoh K,, 2009. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol. Immunol. 53, 41– 44. 19161556
  56. Schelenz S,, 2016. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob. Resist. Infect. Control. 5, 35. 27777756 PMC5069812
  57. Selmecki A,, 2006. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 313, 367– 370. 16857942 PMC1717021
  58. Sexton DJ,, 2018a. Evaluation of a new T2 magnetic resonance assay for rapid detection of emergent fungal pathogen Candida auris on clinical skin swab samples. Mycoses 61, 786– 790. 29938838
  59. Sexton DJ,, 2018b. Direct detection of emergent fungal pathogen Candida auris in clinical skin swabs by SYBR green-based quantitative PCR assay. J. Clin. Microbiol. 56, e01337– e1418. 30232130 PMC6258843
  60. Shin JH,, 2012. Detection of amphotericin B resistance in Candida haemulonii and closely related species by use of the Etest, Vitek-2 yeast susceptibility system, and CLSI and EUCAST broth microdilution methods. J. Clin. Microbiol. 50, 1852– 1855. 22442324 PMC3372122
  61. Soczo G,, 2007. In vitro study of Candida tropicalis isolates exhibiting paradoxical growth in the presence of high concentrations of caspofungin. Antimicrob. Agents Chemother. 51, 4474– 4476. 17923496 PMC2168010
  62. Tsay S,, 2017. Notes from the field: ongoing transmission of Candida auris in health care facilities - United States, June 2016-May 2017. MMWR Morb. Mortal. Wkly Rep. 66, 514– 515. 28520710 PMC5657645
  63. Turnidge J,, 2006. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin. Microbiol. Infect. 12, 418– 425. 16643517
  64. Vallabhaneni S,, 2016. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus - United States, May 2013-August 2016. MMWR Morb. Mortal. Wkly Rep. 65, 1234– 1237. 27832049
  65. Vatanshenassan M,, 2019. Candida auris identification and rapid antifungal susceptibility testing against echinocandins by MALDI-TOF MS. Front. Cell. Infect. Microbiol. 9, 20. 30834236 PMC6387932
  66. Wanger A,, 1995. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob. Agents Chemother. 39, 2520– 2522. 8585737 PMC162976
  67. Wiederhold NP,, 2019. The fungal Cyp51-specific inhibitor VT-1598 demonstrates in vitro and in vivo activity against Candida auris. Antimicrob. Agents Chemother. 63, e02233– e2318. 30530603 PMC6395925
  68. Zhao M,, 2018. In vivo pharmacokinetics and pharmacodynamics of APX001 against Candida spp. in a neutropenic disseminated candidiasis mouse model. Antimicrob. Agents Chemother. 62, e02542– e2617. 29378706 PMC5913987

Cited by

Sorted by citations

Authors
Lockhart, S. R.
Affiliations
Centers for Disease Control and Prevention (US)
Corresponding author
Lockhart, Shawn R.
ORCID
Lockhart, Shawn R.
Venue
Fungal Genetics and Biology
Publisher
Elsevier BV
Published
2019-10
Volume
131
Pages
103243
ISSN
1087-1845 (ISSN-L)
DOI
10.1016/j.fgb.2019.103243
PMC
PMC12012538
OpenAlex
W2951622756
Cited by
205
References
13
Citations by year
2026: 39 · 2025: 26 · 2024: 27 · 2023: 29 · 2022: 25 · 2021: 26 · 2020: 25 · 2019: 8
FWCI
2.94
Type
journal article
Language
en
Open access
Licence
Locations
  • Fungal Genetics and Biology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institutes of Health (CC999999)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Yeasts and Rust Fungi Studies
  • Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
Keywords
Candida auris, antifungal resistance, multidrug resistance, echinocandin resistance, fluconazole resistance, amphotericin B resistance, acquired resistance, resistance mechanisms, antifungal susceptibility testing, emerging fungal pathogens
MeSH terms
Aminopyridines, Amphotericin B, Antifungal Agents, Azoles, Candida, Candidiasis, Humans, Isoxazoles, Microbial Sensitivity Tests, Pyridines, Tetrazoles, Fluconazole, Drug Resistance, Multiple, Fungal, Echinocandins, 14-alpha Demethylase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review